» Articles » PMID: 35525914

Pharmacogenomics of in Vitro Response of the NCI-60 Cancer Cell Line Panel to Indian Natural Products

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 May 7
PMID 35525914
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Indian natural products have been anecdotally used for cancer treatment but with limited efficacy. To better understand their mechanism, we examined the publicly available data for the activity of Indian natural products in the NCI-60 cell line panel.

Methods: We examined associations of molecular genomic features in the well-characterized NCI-60 cancer cell line panel with in vitro response to treatment with 75 compounds derived from Indian plant-based natural products. We analyzed expression measures for annotated transcripts, lncRNAs, and miRNAs, and protein-changing single nucleotide variants in cancer-related genes. We also examined the similarities between cancer cell line response to Indian natural products and response to reference anti-tumor compounds recorded in a U.S. National Cancer Institute (NCI) Developmental Therapeutics Program database.

Results: Hierarchical clustering based on cell line response measures identified clustering of Phyllanthus and cucurbitacin products with known anti-tumor agents with anti-mitotic mechanisms of action. Curcumin and curcuminoids mostly clustered together. We found associations of response to Indian natural products with expression of multiple genes, notably including SLC7A11 involved in solute transport and ATAD3A and ATAD3B encoding mitochondrial ATPase proteins, as well as significant associations with functional single nucleotide variants, including BRAF V600E.

Conclusion: These findings suggest potential mechanisms of action and novel associations of in vitro response with gene expression and some cancer-related mutations that increase our understanding of these Indian natural products.

Citing Articles

A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance.

Zhang Q, Luo Y, Qian B, Cao X, Xu C, Guo K Aging (Albany NY). 2024; 16(9):8000-8018.

PMID: 38709280 PMC: 11132014. DOI: 10.18632/aging.205800.


Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials.

Wang X, Chan Y, Wong K, Yoshitake R, Sadava D, Synold T Cancers (Basel). 2023; 15(3).

PMID: 36765659 PMC: 9913787. DOI: 10.3390/cancers15030701.

References
1.
Huang Y, Dai Z, Barbacioru C, Sadee W . Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005; 65(16):7446-54. DOI: 10.1158/0008-5472.CAN-04-4267. View

2.
Tong R, Wu X, Liu Y, Liu Y, Zhou J, Jiang X . Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway. Oxid Med Cell Longev. 2020; 2020:2543504. PMC: 7317311. DOI: 10.1155/2020/2543504. View

3.
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

4.
Subramani R, Gonzalez E, Nandy S, Arumugam A, Camacho F, Medel J . Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway. Oncotarget. 2016; 8(7):10891-10904. PMC: 5355232. DOI: 10.18632/oncotarget.8055. View

5.
Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, Rubinstein L . Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989; 81(14):1088-92. DOI: 10.1093/jnci/81.14.1088. View